Company Overview - BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, azelaprag, is an orally available small molecule agonist of APJ, which has shown potential in promoting metabolism and preventing muscle atrophy during bed rest in a Phase 1b clinical trial [3] - BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for treating obesity in older adults in mid-2024 [3] Product Development - Azelaprag has potential as an oral regimen to enhance weight loss and improve body composition in patients undergoing obesity therapy with incretin drugs [3] - The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors aimed at treating diseases driven by neuroinflammation [3] - BioAge's preclinical programs leverage insights from its discovery platform based on human longevity data to address key pathways in metabolic aging [3] Upcoming Events - BioAge Labs will present at the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic on December 19, 2024, from 11 AM to 12 PM EST [1] - A live webcast of the presentation will be available, with replays accessible in the investor section of the company's website for 30 days following the event [2]

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42279 BIOAGE LABS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4721157 ( State or other jurisdict ...

Clinical Trials and Drug Development - BioAge initiated the Phase 2 STRIDES trial for azelaprag in combination with tirzepatide for obesity treatment, with top-line results expected in Q3 2025[3] - Research and development expenses increased by $13.5 million to $20.0 million in Q3 2024, primarily due to the Phase 2 STRIDES trial and azelaprag manufacturing costs[5] - Azelaprag, BioAge's lead product candidate, is an oral small-molecule APJ agonist with potential to enhance weight loss and improve body composition in obesity therapy[9] - BioAge is developing NLRP3 inhibitors for neuroinflammatory diseases and has preclinical programs targeting metabolic aging pathways[10] Financial Performance and Funding - The company completed a $238.3 million IPO and private placement, with net proceeds of approximately $189.5 million, extending cash runway into 2029[1][4] - Net loss for Q3 2024 was $23.4 million, or $6.70 per share, compared to a net loss of $14.6 million, or $8.74 per share, in Q3 2023[7] - As of September 30, 2024, BioAge had $334.5 million in cash and cash equivalents, sufficient to fund operations into 2029[8] - Total IPO proceeds, including underwriters' additional share purchases, yielded approximately $217.1 million in net proceeds[4][8] Corporate Governance and Leadership - The company appointed Jean-Pierre Garnier, former CEO of GSK, as Chair of the Board of Directors[4] Operational Expenses - General and administrative expenses rose by $1.3 million to $4.7 million in Q3 2024, driven by increased stock-based compensation[6]

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabol ...